Andy Sargeantson

Director at Sunland Trading, Inc.
  • Claim this Profile
Contact Information

Topline Score

Topline score feature will be out soon.

Bio

Generated by
Topline AI

You need to have a working account to view this content.
You need to have a working account to view this content.

Experience

    • Wholesale Import and Export
    • 1 - 100 Employee
    • Director
      • Jul 2013 - Present

      Sunland Trading is a family-owned, second-generation importer of honey. The company’s focus is on the bulk importation of raw honeys, of all floral types and colors, from across the globe. Sunland Trading is a family-owned, second-generation importer of honey. The company’s focus is on the bulk importation of raw honeys, of all floral types and colors, from across the globe.

    • Wholesale Import and Export
    • 1 - 100 Employee
    • Co-Founder
      • Aug 2017 - Jun 2021

      Importer of specialty coffees from Colombia, Ethiopia, Burundi, Mexico and various other countries to the US, UK and EU markets. Exporter of Colombian coffee globally. Importer of specialty coffees from Colombia, Ethiopia, Burundi, Mexico and various other countries to the US, UK and EU markets. Exporter of Colombian coffee globally.

    • United States
    • Financial Services
    • 700 & Above Employee
    • Associate, Healthcare Equity Capital Markets
      • Jul 2011 - Jul 2013

      As an associate in Healthcare Equity Capital Markets at Morgan Stanley, Andrew works with and advises healthcare clients on equity issuance strategies and execution. Andrew develops company-, market- and sector-specific positioning strategies for equity issuance clients for both IPOs and follow-on offerings; marketing and interacting with both investors and issuers during execution period and pricing recommendation. Andrew is also heavilly involved in generating ideas for quantitative and qualitative pitch materials and helping create and execute the materials for equity clients. Andrew received an Accelerated Career Path promotion from analyst to associate without attending business school.Andrew has executed over 12 follow-on and IPOs since 2012, including the $2.6Bn Zoetis IPO, filed $600MM Quintiles IPO, $1.1Bn HCA block, $322MM in 3 Synageva follow-ons and $260MM in 2 Infinity Pharma follow-ons

    • Analyst, Financial Institutions Equity Capital Markets
      • Jul 2010 - Jul 2011

      As a third year analyst in Financial Institutions Equity Capital Markets, Andrew provided clients with tailored analytical materials detailing equity capital raising strategies and execution alternatives given company-specific ownership structures, market environment considerations and funding needs. He managed and executed equity offerings for U.S. financial institutions, including developing positioning and roadshow strategies, reviewing legal documents and providing market updates and offering summaries. He was the sole analyst on the U.S. Treasury's $32Bn Citigroup dribble out and secondary offering.

    • Analyst, Financial Institutions Investment Banking
      • Jul 2008 - Jul 2010

      For two years as an analyst in the FIG Investment Banking Group at Morgan Stanley, Andrew performed company valuation by applying techniques such as comparable trading, precedent transaction and discounted cash flow analyses through the creation and manipulation of accretion / dilution and operating models. He also analyzed M&A strategic alternatives for financial technology and banking companies, focusing on the strategic fit, pro forma capital and earnings impacts and internal rate of return. He worked on the $604MM acquisition of Climate Exchange by IntercontinentalExchange (client) and the $738MM acquisition of Financial Federal by People's United (client).

Education

  • Bowdoin College
    Bachelor of Arts (B.A.), Economics
    2005 - 2008

Community

You need to have a working account to view this content. Click here to join now